All Posts:ITP

• Drug Found to be Effective in Difficult to Treat Autoimmune Blood Disorder

  Patients taking efgartigimod, a drug being studied for use to treat chronic primary immune thrombocytopenia (ITP), exhibited a significantly greater improvement in platelet counts which are essential to clotting and stopping bleeding, compared to those taking a placebo, according to results reported from the ADVANCE IV clinical trial, which was conducted globally, including at Georgetown University Medical Center.

  Category: News Release Tags: bleeding disorders, hematology, ITP, research